论文部分内容阅读
目的评价c-Met蛋白在乳腺癌中的表达状况及与临床病理指标的可能关系。方法采用免疫组织化学方法检测100例乳腺浸润性导管癌c-Met蛋白的表达,并评价它们与病理分级、临床分期、转移以及预后之间的关系。结果 100例乳腺癌组织c-Met表达阳性43例,阴性57例。c-Met的表达与乳腺癌淋巴结转移(P=0.0001)、临床分期(P=0.001)以及预后(P=0.009)密切相关;与年龄(P=0.784)、肿瘤大小(P=0.890)和肿瘤病理分级(P=0.456)无关。结论 c-Met的表达在乳腺癌中有统计学意义,其表达随转移和临床分期升高而增强,提示其对乳腺癌的发生及侵袭、转移起着重要作用。
Objective To evaluate the expression of c-Met protein in breast cancer and its possible relationship with clinicopathological parameters. Methods Immunohistochemical method was used to detect the expression of c-Met protein in 100 cases of invasive ductal carcinoma of the breast, and to evaluate their relationship with pathological grade, clinical stage, metastasis and prognosis. Results 100 cases of breast cancer c-Met expression was positive in 43 cases, negative 57 cases. The expression of c-Met was closely related to lymph node metastasis (P = 0.0001), clinical stage (P = 0.001) and prognosis (P = 0.009) Pathological grade (P = 0.456) was not related. Conclusions The expression of c-Met is statistically significant in breast cancer. The expression of c-Met is increased with the metastasis and clinical stage, suggesting that c-Met plays an important role in the occurrence, invasion and metastasis of breast cancer.